Advances in the Treatment of Relapsed/Refractory Immune Thrombocytopenia

To claim CME credit, visit https://i3health.com/oda-itp Immune thrombocytopenia is an acquired immune-mediated disorder with no known cause. Effective management is limited by lack of specific diagnostic criteria and other current gaps in knowledge. This episode of Oncology Data Advisor will focus on advances in the treatment of relapsed or refractory immune thrombocytopenia. It features perspectives from two noted experts in the field: Dr. Keith McCrae, Director of Benign Hematology at the Cleveland Clinic Taussig Cancer Center; and Ms. Phyllis McKiernan, Advanced Practice Nurse in Blood & Marrow Stem Cell Transplantation at the John Theurer Cancer Center, Hackensack Meridian Health.